SCHEMBL30217819

SCHEMBL30217819

COc1cc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(C(=O)O)c2nn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.43
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
PBRM1 Q86U86 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CKS1B P61024 2/20 0.42
SKP1 P63208 2/20 0.42
SKP2 Q13309 2/20 0.42
KIT P10721 1/20 0.41
BACE1 P56817 1/20 0.40
SLC2A1 P11166 1/20 0.40
TP53 P04637 1/20 0.40
PTPN11 Q06124 1/20 0.40
PIK3CA P42336 1/20 0.40
TLR9 Q9NR96 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GBA1 P04062 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25096266 1.00 GPR119 (0.43) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL25096775 0.91 SMARCA2 (0.42) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL30217858 0.91 SMARCA2 (0.42) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL30217579 0.88 GPR119 (0.42) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL25097076 0.88 GPR119 (0.42) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL25096995 0.87 SMARCA2 (0.44) GPR119SMARCA2SMARCA4PBRM1CKS1B
SCHEMBL30161994 0.87 SMARCA2 (0.44) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL25097057 0.84 SMARCA2 (0.42) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL30217772 0.84 SMARCA2 (0.42) GPR119SMARCA2SMARCA4PBRM1SMN1; SMN2
SCHEMBL25096668 0.84 CKS1B (0.43) GPR119CKS1BSKP1SKP2KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
CN-118234724-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-06-21 CN disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 GPR119 4012/4885SMARCA2 2493/4885SMARCA4 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.